| 2026-08-04 | Press release | IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update |
| 2026-08-04 | 8-K | Form 8-K, Item 2.02 results |
| 2026-08-04 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2026-07-31 | Press release | IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) |
| 2026-07-27 | Press release | IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates Part 2 Monothe |
| 2026-07-17 | Press release | IDEAYA Biosciences Announces ESMO 2026 Presentations for Darovasertib and IDE849 Clinical Programs |
| 2026-06-26 | Press release | IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) |
| 2026-06-23 | 8-K | Form 8-K, Item 5.07 |
| 2026-06-17 | Press release | IDEAYA Biosciences Announces Yujiro S. Hata Elected Chairman of its Board of Directors |
| 2026-06-15 | Press release | IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Cl |
| 2026-06-10 | Press release | IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Share |
| 2026-06-10 | 8-K | Form 8-K, Item 8.01 |
| 2026-06-08 | Press release | IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants |
| 2026-06-08 | Press release | IDEAYA Announces Pricing of $300 Million Offering of Common Stock and Pre-Funded Warrants |
| 2026-06-03 | Press release | IDEAYA Biosciences Announces Clinical Collaboration with Roche in MTAP-Deleted RAS-Mutant Pancreatic Cancer |
| 2026-06-03 | 8-K | Form 8-K, Item 8.01 |
| 2026-06-01 | Press release | IDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial of the Darovasertib |
| 2026-06-01 | 8-K | Form 8-K, Item 7.01 |
| 2026-05-31 | Deck | Investor presentation · May 2026 |
| 2026-05-29 | Press release | IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) |
| 2026-05-26 | Press release | IDEAYA Biosciences Announces Participation at the 2026 Jefferies Global Healthcare Conference |
| 2026-05-05 | Press release | IDEAYA Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update |
| 2026-05-05 | 8-K | Form 8-K, Item 2.02 results |
| 2026-05-05 | 8-K | Form 8-K, Item 8.01 |
| 2026-05-05 | 10-Q | Form 10-Q for the quarter ended Mar 31 |
| 2026-05-04 | Deck | Investor presentation · Q2 2026 · May 2026 |
| 2026-05-01 | Press release | IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) |
| 2026-04-30 | Press release | IDEAYA Biosciences to Initiate New Drug Application Submission from the Darovasertib OptimUM-02 Trial under the Oncology |
| 2026-04-29 | Proxy | Definitive proxy statement |
| 2026-04-21 | Press release | IDEAYA Biosciences Announces Late-Breaking Abstract Oral Presentation at ASCO 2026 to Provide Complete Data from Phase 2 |
| 2026-04-13 | Press release | IDEAYA Biosciences and Servier Announce Positive Topline Results from Phase 2/3 Registrational Trial (OptimUM-02) of Dar |
| 2026-04-13 | Deck | Investor presentation · Apr 2026 |
| 2026-04-13 | 8-K | Form 8-K, Item 8.01 |
| 2026-04-10 | Press release | IDEAYA Biosciences to Announce Topline Results from Phase 2/3 OptimUM-02 Trial in Metastatic Uveal Melanoma on Monday, A |
| 2026-04-09 | 8-K | Form 8-K, Item 8.01 |
| 2026-04-06 | Press release | IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE574, a Potential First-In Class Dual Inhibitor of |
| 2026-03-30 | Press release | IDEAYA Biosciences Announces First-Patient-In for Phase 1 Combination Study of IDE849, DLL3 TOP1 ADC, and IDE161, PARG I |
| 2026-03-27 | Press release | IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) |
| 2026-03-22 | Press release | IDEAYA Biosciences Upcoming Investor Relations Events and Updated Darovasertib Topline Results Guidance from Phase 2/3 O |
| 2026-03-18 | Press release | IDEAYA Biosciences Announces Upcoming Presentations at AACR 2026 Highlighting Multiple Clinical Stage Pipeline Programs |